If a video about BPC-157 and knee cartilage crossed your feed recently, you're not the only one who searched for this. The claim moves fast because it's genuinely exciting: a peptide that could regrow cartilage would matter to a lot of people, since cartilage is one of the few tissues in the body that doesn't repair itself well on its own. The research behind the claim is real. It just doesn't say what the headline says, and the gap between those two things is worth understanding before you decide what to make of it.
What cartilage actually is, and why the claim is a big deal
Cartilage is the smooth, rubbery tissue that cushions your joints, and it has almost no blood supply of its own. That's the whole problem. Most tissue in your body heals by recruiting nutrients and repair cells through blood vessels, and cartilage largely can't do that, which is a big part of why joint damage tends to be permanent rather than something that heals like a cut. Any compound that could change that dynamic would be a meaningful finding, which is exactly why a claim like this spreads.
What the animal research actually found
BPC-157 has a genuinely large body of preclinical research behind it, meaning studies done in cells and animal models rather than people. A 2025 systematic review in HSS Journal looked specifically at BPC-157's use in orthopedic and sports medicine contexts, covering fractures, tendon injuries, ligament tears, and muscle damage across multiple animal studies. The pattern the researchers found was consistent: the preclinical data is positive across nearly every injury type tested, and independent labs have reproduced key findings rather than just one group publishing repeatedly.[1]
A separate 2025 review in Current Reviews in Musculoskeletal Medicine dug into why researchers think this happens. BPC-157 appears to activate a signaling pathway (VEGFR2, alongside nitric oxide production) that promotes new blood vessel growth, among other repair-related effects. In a tissue like cartilage that struggles precisely because it lacks blood supply, that mechanism is the reason researchers find the cartilage angle interesting in the first place. The same review is candid about where the evidence stops: despite that broad preclinical support, only three small human pilot studies on BPC-157 exist in total, and the authors conclude the compound should be considered investigational until larger, well-designed human trials are done.[2]
What the human study actually measured
Here's where the claim gets stretched. The human data most often cited for this is a 2021 retrospective case series published in Alternative Therapies in Health and Medicine, where 16 patients with various types of knee pain received an intra-articular injection (directly into the joint) of BPC-157, some combined with another peptide called TB-500. Fourteen of the sixteen patients reported significant pain relief.[3]
That's a real and interesting result, and it's worth taking seriously. But look closely at what was actually measured: patient-reported pain, not cartilage. No one in that study had imaging (like an MRI) or a biopsy before and after to confirm whether cartilage tissue itself had changed. There was also no control group, meaning no comparison against patients who didn't receive the injection, which makes it hard to separate the effect of the peptide from the placebo effect or the injection process itself. A retrospective case series of 16 people is a starting point for a hypothesis. It is not confirmation that cartilage regrew.
So what should you actually take from this?
The animal research is genuinely promising, and the proposed mechanism (improving blood vessel growth in a tissue that badly needs it) is a reasonable scientific story, not a stretch. That's worth being excited about. What hasn't happened yet is the study that would actually confirm cartilage regrowth in humans: something with imaging or biopsy evidence, a control group, and enough participants to trust the result. Until that exists, "BPC-157 regrows cartilage" is an extrapolation from animal data and a pain-relief signal in 16 people, not a settled finding.
It's also worth knowing that BPC-157 doesn't have FDA approval for any use, and it's classified as a non-approved substance by organizations that regulate research and competitive use. None of that means the research direction isn't worth following. It just means the evidence hasn't caught up to the claim yet, and that's a distinction worth holding onto rather than something to be talked out of.
Where to go from here
For the full research picture on BPC-157, including its other studied uses and the complete citation list, see the BPC-157 research notes page. If you're comparing current per-mg pricing across vendors, the price comparison tool pulls live data rather than relying on any single seller's listed price.
If you want the fuller context on how to weigh preclinical evidence against approved-drug evidence in general, not just for this compound, Research Peptides vs. FDA-Approved Compounds covers that spectrum in more depth.